Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

<p><strong>Background:</strong> A blood-stage Plasmodium falciparum malaria vaccine would provide a second line of defence to complement partially effective or waning immunity conferred by the approved pre-erythrocytic vaccines. RH5.1 is a soluble protein vaccine candidate for bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Silk, SE, Kalinga, WF, Salkeld, J, Mtaka, IM, Ahmed, S, Milando, F, Diouf, A, Bundi, CK, Balige, N, Hassan, O, Mkindi, CG, Rwezaula, S, Athumani, T, Mswata, S, Lilolime, NS, Simon, B, Msami, H, Mohamed, M, David, DM, Mohammed, L, Nyaulingo, G, Mwalimu, B, Juma, O, Mwamlima, TG, Sasamalo, IA, Mkumbange, RP, Kamage, JJ, Barrett, JR, King, LDW, Hou, MM, Pulido, D, Carnrot, C, Lawrie, AM, Cowan, RE, Nugent, FL, Roberts, R, Cho, J-S, Long, CA, Nielsen, CM, Miura, K, Draper, SJ, Olotu, AI, Minassian, AM
Formato: Journal article
Lenguaje:English
Publicado: Elsevier 2024

Ejemplares similares

Ejemplares similares